FDA Clears New Underarm Sweat Control Patch

The Brella SweatControl Patch utilizes Candesant’s patented TAT (targeted alkali thermolysis) technology.

The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. 

The Brella SweatControl Patch provides a new in-office approach to sweat control that is fast, non-invasive, needle-free, aluminum-free, and affordable, with results lasting three to four months.Consisting of a sodium sheet with an adhesive overlay, the Brella SweatControl Patch is a single-use disposable patch applied to a patient’s underarm by a health care provider for up to three minutes. 

It utilizes Candesant’s patented TAT (targeted alkali thermolysis) technology, which is based on the scientific principle that heat is generated when sodium comes in contact with water in sweat. The thermal energy created by the sodium sheet is precisely localized, microtargeting sweat glands to significantly reduce sweat production.

The Brella SweatControl Patch is the first clinical application to harness and target this property of sodium and is the only patented medical device based on it.

Brella is the first FDA-cleared product from Candesant Biomedical.